09/27/23 4:25 PMNYSE : TAK fda approvalU.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative ColitisTakeda today announced that the U.S. Food and Drug Administration has approved a subcutaneous administration of ENTYVIO ® for maintenance therapy in adults with moderately to severely...RHEA-AIneutral
09/25/23 8:44 AMNYSE : TAK Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or HypogammaglobulinemiaApproval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU CUVITRU is Takeda’ s First Subcutaneous Immunoglobulin Plasma Therapy in Japan, Delivering on the Company’ s Commitment to Reach Patients with High Unmet Needs. The approval marks Takeda’ s first subcutaneous immunoglobulin...RHEA-AIneutral
09/20/23 8:00 AMNYSE : TAK clinical trialTakeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)Takeda today announced that the U.S. Food and Drug Administration has accepted for review its New Drug Application resubmission for TAK-721 which is being investigated for the short-term treatment of eosinophilic esophagitis, a chronic inflammatory disease that can cause damage to the esophagus. 1 The resubmission is intended...RHEA-AIneutral
09/13/23 10:00 AMNYSE : TAK partnershipTakeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 CountriesTakeda’ s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 24.2 Billion Since Program Inception in 2016. More Than 24,500 Takeda Employees Worldwide Participated in the Selection of the Five New Partnerships: Society for Family Health Rwanda, Relief International, Mercy Corps, University of Nairobi and Partners In Health. With This...RHEA-AIneutral
09/13/23 8:00 AMNYSE : TAK clinical trialTakeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s DiseaseTakeda today announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for the investigational subcutaneous administration of...RHEA-AIneutral
09/11/23 6:45 AMNYSE : TAK clinical trialTakeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic ArthritisTakeda today announced positive topline...RHEA-AIneutral
08/28/23 6:30 AMNasdaq, NYSE : IMGN, TAK ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in JapanImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan. "As a leader in the development and commercialization of novel products in oncology for more than...RHEA-AIpositive
08/07/23 4:01 PMNasdaq, NYSE : ARWR, GSK, TAK earningsArrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter ResultsArrowhead Pharmaceuticals, Inc. today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details.RHEA-AIneutral
07/27/23 2:00 AMNYSE : TAK earningsTakeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch ProductsTakeda today announced strong financial results for the first quarter of fiscal year 2023. In FY2022, Takeda paid USD 3.0 billion out of USD 4.0 billion upfront payment related to the acquisition of TAK-279. For the remaining USD 1.0 billion payment, Takeda paid USD 0.9 billion in April 2023, with USD 0.1 billion to be paid in August...RHEA-AIneutral
07/26/23 5:11 PMNYSE : TAK clinical trialThe New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated Statistically Significant Improvement in Daytime Wakefulness; Weekly Cataplexy Rates Reduced or Abolished at All Doses Compared to Placebo Findings Indicate...RHEA-AInegative